What's new in the 2009 US guidelines for prevention and treatment of opportunistic infections among adults and adolescents with HIV?
Despite dramatic declines in the incidence of opportunistic infections (OIs) in the United States, they remain an important cause of morbidity and mortality for HIV-infected persons. Previously separate guidelines on the prevention of OIs and on the treatment of OIs have been combined recently into an updated single document; the present article reviews salient changes to and new information contained in this guidance. Chapters on hepatitis B virus infection and tuberculosis have been expanded substantially, and each chapter now includes information on immune reconstitution inflammatory syndrome. In addition, there is detailed discussion on the role of antiretroviral therapy in OI prevention and issues concerning the initiation of antiretroviral therapy during treatment of an acute OI. In the future, these guidelines will likely be maintained as an internet-based document to facilitate wider dissemination and more rapid updates.
Brooks
John T
JT
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Kaplan
Jonathan E
JE
Masur
Henry
H
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000517:prevention & control* / Q000821:virology; D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000494:pharmacology; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000628:therapy; D006801:Humans; D007114:Immunization; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000628:therapy; D014481:United States
D019380:Anti-HIV Agents